Drug price regulation experiences in selected countries: lessons for Brazil

Authors

DOI:

https://doi.org/10.22239/2317-269X.01730

Keywords:

Regulamentação Governamental; Preço de Medicamento; Medicamentos Genéricos

Abstract

Introduction:Price regulation in the pharmaceutical market is common to countries at different levels of development, but the motivation for its implementation differs between developed and developing countries. Objective:To discuss the drug price regulation in Brazil and the need for improvements based on experiences and evidences of drug price regulation in selected countries. Method:Review of the literature on regulatory models of drug prices in selected countries. Results:Based on the systematized literature, an analysis of different types of drug price regulation by group (European and developing countries) was carried out. Conclusions:The literature review was used to observe the different drug price regulations among countries, and to identify examples on how to improve the current regulation in Brazil to achieve more desirable results.

Downloads

Download data is not yet available.

Author Biographies

  • Caroline Miranda Alves de Souza, Institute of Economics, Federal University of Rio de Janeiro

    Graduated in Economic Sciences from the Federal University of Rio de Janeiro (2016). Master in Economics of Industry and Technology from the Federal University of Rio de Janeiro (2020). PhD student in Public Policy, Strategies and Development at the Federal University of Rio de Janeiro. He has experience in the area of Economics, acting mainly on the following themes: innovation, regulation, industrial economics, pharmaceutical industry, health and development.

  • Julia Paranhos, Institute of Economics, Federal University of Rio de Janeiro

    Associate Professor at the Federal University of Rio de Janeiro and coordinator of the Innovation Economics Group at the UFRJ Institute of Economics. Associate Director of Graduation at IE / UFRJ between August 2015 and July 2017. Graduated in Economic Sciences from UFRJ (2004), Master in Industrial Economics from the Federal University of Santa Catarina (2006) and PhD in Economics from Industry and Technology from UFRJ (2010) with a sandwich doctorate at Science and Technology Policy Research - SPRU (2009). Member of the Brazilian Association of Industrial Economics and Innovation (ABEIN). He has experience in the area of Economics, with an emphasis on Innovation, acting mainly on the themes: innovation management, industrial and innovation policy, university-company relationship and industrial property, especially in the pharmaceutical sector.

  • Lia Hasenclever, Institute of Economics, Federal University of Rio de Janeiro

    Graduated in Economics from the Federal University of Rio de Janeiro (1977), Master in Industrial Economics from the Federal University of Rio de Janeiro (1988) and doctorate in Postgraduate Program in Production Engineering from the Federal University of Rio de Janeiro (1997). He is currently Professor of the Graduate Program in Regional Planning and City Management and Retired Professor at the Federal University of Rio de Janeiro. He has experience in the area of Economics, with an emphasis on Industrial Organization, Industrial and Innovation Studies, and Development, acting mainly in the following applications: local economic development; industrial and innovation studies in the pharmaceutical, petrochemical, oil, textile and clothing industries; and the state of Rio de Janeiro and its regions.

Published

2021-08-31

Issue

Section

Articles

How to Cite

Drug price regulation experiences in selected countries: lessons for Brazil. (2021). Health Surveillance under Debate: Society, Science & Technology , 9(3), 14-22. https://doi.org/10.22239/2317-269X.01730

Similar Articles

1-10 of 680

You may also start an advanced similarity search for this article.